Amryt Pharma PLC Grant of Options & PDMR Dealings (0554Y)
01 December 2017 - 6:01PM
UK Regulatory
TIDMAMYT
RNS Number : 0554Y
Amryt Pharma PLC
01 December 2017
1 December 2017
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Grant of Options and Notification of Transactions by Persons
Discharging Managerial Responsibilities
Amryt announces that the Remuneration Committee has approved the
grant of 2,885,582 share options ("Options") to subscribe for
ordinary shares of 1p each in the Company ("Shares") under the
Employee Share Option Plan 2016 (the "Plan") to Joe Wiley, CEO, and
Rory Nealon, CFO, details of which are set out in the table
below.
The Options have an exercise price of 20.12p ("Exercise Price").
These options may be exercised as follows:
-- 25% of the total Options granted may be exercised
12 months after the date of grant;
-- a further 25% of the total Options granted
may be exercised 24 months after the date
of grant; and
-- the balance of the Options may be exercised
36 months after the date of grant.
All Options are subject to change of control provisions and
expire on the seventh anniversary of their grant.
Following the grants of these options, the following Directors
have the following options:
Director Options granted Total Options now held
------------- ---------------- -----------------------
Joe Wiley 2,061,130 2,061,130
------------- ---------------- -----------------------
Rory Nealon 824,452 824,452
------------- ---------------- -----------------------
PDMR Dealings
The notification of dealing forms for each Director can be found
below. This announcement is made in accordance with Article 19 of
the EU Market Abuse Regulation 596/2014.
1. Details of the person discharging managerial
responsibilities / person closely associated
---- ------------------------------------------------------------------
a) Name Joe Wiley
---- ----------------------------- -----------------------------------
2. Reason for the notification
---- ------------------------------------------------------------------
a) Position / status Director
---- ----------------------------- -----------------------------------
b) Initial notification Initial notification
/ amendment
---- ----------------------------- -----------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- ------------------------------------------------------------------
a) Name Amryt Pharma plc
---- ----------------------------- -----------------------------------
b) Legal entity 213800BOS8WAJO2BEQ38
identifier
---- ----------------------------- -----------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- ------------------------------------------------------------------
a) Description of Ordinary shares of GBP0.01
the financial each
instrument, type
of instrument
Identification ISIN: GB00BDD1LS57
code
---- ----------------------------- -----------------------------------
b) Nature of the Grant of pptions under
transaction the Employee Share Option
Plan 2016 with an exercise
price of 20.12p to purchase
2,061,130 ordinary shares.
---- ----------------------------- -----------------------------------
c) Currency British Pounds
---- ----------------------------- -----------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
---- ----------------------------- --------------- ---------------
N/A 2,061,130
-------------------------------------------------- ---------------
e) Aggregated information
* Aggregated volume 2,061,130
N/A
* Aggregated price
---- ----------------------------- -----------------------------------
f) Date of the transaction 29 November 2017
---- ----------------------------- -----------------------------------
g) Place of the Outside a trading venue
transaction
---- ----------------------------- -----------------------------------
1. Details of the person discharging managerial
responsibilities / person closely associated
---- ------------------------------------------------------------------
a) Name Rory Nealon
---- ----------------------------- -----------------------------------
2. Reason for the notification
---- ------------------------------------------------------------------
a) Position / status Director
---- ----------------------------- -----------------------------------
b) Initial notification Initial notification
/ amendment
---- ----------------------------- -----------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- ------------------------------------------------------------------
a) Name Amryt Pharma plc
---- ----------------------------- -----------------------------------
b) Legal entity 213800BOS8WAJO2BEQ38
identifier
---- ----------------------------- -----------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- ------------------------------------------------------------------
a) Description of Ordinary shares of GBP0.01
the financial each
instrument, type
of instrument
Identification ISIN: GB00BDD1LS57
code
---- ----------------------------- -----------------------------------
b) Nature of the Grant of options under
transaction the Employee Share Option
Plan 2016 with an exercise
price of 20.12p to purchase
824,452 ordinary shares.
---- ----------------------------- -----------------------------------
c) Currency British Pounds
---- ----------------------------- -----------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
---- ----------------------------- --------------- ---------------
N/A 824,452
-------------------------------------------------- ---------------
e) Aggregated information
* Aggregated volume 824,452
N/A
* Aggregated price
---- ----------------------------- -----------------------------------
f) Date of the transaction 29 November 2017
---- ----------------------------- -----------------------------------
g) Place of the Outside a trading venue
transaction
---- ----------------------------- -----------------------------------
Enquiries:
C/o KTZ Communications
Amryt Pharma plc (details below)
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Edward Mansfield, Mark
Percy
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene
Bermont-Penn, Emma Pearson
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty biopharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the European Economic Area, Middle
East and North Africa, Turkey and Israel. Lojuxta is used to treat
a rare life-threatening disease called Homozygous Familial
Hypercholesterolemia, which impairs the body's ability to remove
LDL cholesterol ("bad" cholesterol) from the blood. This typically
results in extremely high blood LDL cholesterol levels, leading to
aggressive and premature narrowing and blocking of arterial blood
vessels. If left untreated, heart attack or sudden death may occur
in childhood or early adulthood.
Amryt's lead drug candidate, AP101, is a potential treatment for
Epidermolysis bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children for which there is currently no
treatment. It is currently in Phase 3 clinical trials. The global
market opportunity for EB is estimated to be in excess of EUR 1.3
billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHWGGBGGUPMGMU
(END) Dow Jones Newswires
December 01, 2017 02:01 ET (07:01 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024